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www.cdatm.orgAbstractObjective: Soluble CD40 (sCD40) is a potential modulator for both antitumor responses and CD40-based immunotherapy;
however the levels and significance of sCD40 in non-small cell lung cancer (NSCLC) patients with malignant pleural effusion are
unknown.
Methods: Forty-eight patients with lung cancer were treated in our institutions from January 2008 to January 2010. Peripheral
blood and pleural effusion samples were collected from each subject. sCD40 levels in plasma and malignant pleural effusions
supernatant were measured. The CD40L expression on CD3t T-cells was confirmed by flow cytometric direct immunofluorescence
analysis. All patients were followed up after the study ended on January 1, 2010.
Results: Patients with malignant pleural effusion of NSCLC had elevated circulating and pleural effusion levels of sCD40, and
these elevated sCD40 levels were associated with advanced diseases and a poor prognosis.
Conclusions: These findings indicate that elevated sCD40 may have a role in modulating antitumor responses and may also be a
useful prognostic marker.
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Malignant pleural effusions (MPE) worsen the
clinical course of patients with lung cancer.1,2 The
majority of the MPEs develop when tumor cells
directly infiltrate the pleura. Due to mediastinal lymph
node or bronchial obstruction, pulmonary embolism or
superior vena cava syndrome, pleural effusion may
also occur in patients with indirect malignant dis-
eases.3 CD40 is best appreciated as a critical regulatorElsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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B lymphocytes, dendritic cells, and monocytes.4,5
CD40 is also expressed on the surface of many other
normal cells. The global physiologic effect of the
CD40 signaling pathway is profound.4 CD40 ligand
(CD40L), which is also known as CD154, is the chief
ligand described for CD40 and is expressed primarily
by T lymphocytes and platelets. Atherosclerosis, graft
rejection, coagulation, infection control, and autoim-
munity are all regulated by CD40-CD40L
interactions.5,6 In the present study, we provide data
about sCD40 levels in NSCLC patients with malignant
pleural effusion and analyze the relationship between
the levels of sCD40 and the prognosis of patients.
Materials and methods
Patients and study design
Forty-eight patients with lung cancer were treated in
our institutions from January 2008 to January 2010. All
patients (28 males, 20 females with an average age of
64.4 years, ranging from 35 to 82 years old) were
histologically diagnosed with lung cancer and patho-
logically staged according to the Tumor-Node-
Metastasis (TNM) classification.7 Among them, 13
patients were stage I and II, and the other 35 patients
were stage III and IV. No patients had chemotherapy or
immunotherapy within the six weeks preceding the
study. Out of 48 patients, 29 of them with MPE (when
malignant cells were detected in the pleural fluid or in
the pleura with a cytopathological examination) were
enrolled in this study, 17 patients had Performance
Status (PS) ¼ 0e1, 12 patients had PS 2. Two
samples of peripheral blood were successfully obtained
from 26 patients before and after two cycles of
chemotherapy. Eighteen patients experienced progres-
sive disease (PD) and eight patients experienced stable
disease and partial remission (SD þ PR). The same
procedure was also performed in 15 peripheral blood
samples from healthy volunteers.
Enzyme immunoassays and flow cytometric immunofluo-
rescence analysis
Peripheral blood and pleural effusion samples were
withdrawn from each subject after they signed an
informed consent, and anticoagulated in Natrium Cit-
rate. Samples were immediately centrifuged at
3000 r/min for 10 min. sCD40 levels in plasma and
MPE supernatant were measured with an sCD40
enzyme-linked immunosorbent assay kit (eBioscience,USA) according to the manufacturers' instructions.
Peripheral blood mononuclear cells were obtained by
Hypaque-Ficoll gradient centrifugation and then
washed. The CD40L expression on CD3þ T-cells was
confirmed by flow cytometric direct immunofluores-
cence analysis, using CD40L-polyethylene (PE) and
CD3-fluorescein isothiocyanate (FITC) monoclonal
antibodies (BioLegend, USA). All samples were
assayed twice.
Follow-up
All patients were followed up after the study ended
on January 1, 2010 for at least three months unless
deceased occurred. Before the end of the study, the
patients (or their families) were contacted by telephone
to assess the survival status or the date of death.
Statistical analysis
All analyses were performed using GraphPad Prism
5.0 (GraphPad Software, USA); Pearson's correlation,
the t-test, one-way Analysis of Variance (ANOVA),
and Log-rank (ManteleCox) Test were used. Statisti-
cal significance was assumed if a P-value (two tailed)
was less than 0.05. Data are expressed as
mean ± standard deviation (SD).
Results
sCD40 levels in patients' plasma with different TNM
stages and PS score
Levels of sCD40 in the plasma of patients with lung
cancer were higher than in healthy volunteers
(249.60 ± 40.37 pg/ml vs. 128.70 ± 16.49 pg/ml,
P¼ 0.002). Different sCD40 levels were detected in the
patients' plasma with different TNM stages. The sCD40
levels in plasma from patients who at stage IIIeIV,
310.00 ± 51.55 pg/ml (n ¼ 35), were higher than the
levels in patients with stage IeII disease,
87.08 ± 16.74 pg/ml (n ¼ 13) (Fig. 1A). The sCD40
levels from patients with the most advanced lung cancer
stage IV (n ¼ 29) whose PS 2 was 521.7 ± 124.7 pg/
ml (n ¼ 12), higher than in patients with PS ¼ 0e1,
216.00 ± 30.76 pg/ml (n ¼ 17) (Fig. 1B).
Different sCD40 levels pre-chemotherapy and post-
chemotherapy
The sCD40 level of patients after two cycles of
chemotherapy was higher, 193.70 ± 13.17 pg/ml
Fig. 2. Different sCD40 levels pre-chemotherapy and post-
chemotherapy (A), PD and SD þ PR (B).
Fig. 1. Comparison of levels of sCD40 in patients with different
TNM stages (A) and PS scores (B).
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142.00 ± 14.13 pg/ml (n ¼ 26) (Fig. 2A). The sCD40
levels in patients who experienced PD before chemo-
therapy were higher, 161.40 ± 5.05 pg/ml (n ¼ 18)
than in patients who experienced SD þ PR,
98.44 ± 26.21 pg/ml (n ¼ 8) (Fig. 2B).
Relationship among sCD40 levels, CD40Lþ/CD3þ T-
cell ratios, and ADA levels in pleural fluid
The sCD40 levels in pleural fluid were negatively
correlated with CD40Lþ/CD3þ T-cell ratios,
R2 ¼ 0.6588, P ¼ 0.001, (Fig. 3B) and ADA levels,
R2 ¼ 0.4196, P ¼ 0.023, (Fig. 3C) in pleural fluid. The
ADA levels were positively correlated to CD40Lþ/
CD3þT cell ratios, R2 ¼ 0.5663, P ¼ 0.0047 (Fig. 3D).
There was no significant correlation between sCD40
and ADA the levels in plasma (results not shown).
Survival analysis
Median survival time of patients with high sCD40
levels in pleural fluid, more than 200 pg/ml, was
significantly lower compared with those having lower
sCD40 levels, 3.3 months vs. 6.6 months, Chisquare ¼ 4.004, Hazard Ratio ¼ 0.4643, P ¼ 0.045
(Fig. 4).
Discussion
The CD40-CD40L interaction was first shown to
play critical roles in B-cell activation and differentia-
tion. In a recent investigation, it was found that the
physiologic consequences of CD40 signaling were
multifaceted, and even biologically opposed, depend-
ing on the type of cell expressing CD40 and the
microenvironment in which the CD40 signal is pro-
vided. For example, CD40-CD40L engagement in-
duces activation and proliferation of B lymphocytes
but triggers apoptosis of carcinoma cells. The CD40
molecules are found in two forms, membrane-type
(membrane-anchored CD40, mCD40) and soluble
(soluble CD40, sCD40). Fanslow in 1992 was the first
who described sCD40 protein and confirmed sCD40
had the ability to bind CD40L.8 Our study indepen-
dently confirmed the findings of Fanslow that sCD40
could be detected in blood and pleural effusion from
lung cancer patients; we also found that sCD40 levels
from advanced stages of lung cancer were significantly
higher than in early stage disease. After chemotherapy,
Fig. 3. Expression of CD3þCD40Lþ T cells was detected by flow cytometry (A). The levels of sCD40 was negatively correlated with
CD40Lþ/CD3þ T-cell ratios (B) and ADA levels (C). ADA levels were positively correlated with CD40þ/CD3þ T-cell ratios (D).
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chemotherapy, especially in patients who experienced
PD after two cycles of chemotherapy. We postulate that
chemotherapy may elevate sCD40 levels of plasma by
irritating tumor cells and promoting sCD40 secretion.
For those who were not sensitive to chemotherapy,
increased sCD40 levels can act as one of the important
pathways of immune escape for tumor cells.Fig. 4. Kaplan Meier progression free survival curves for patients
with MPE according to sCD40 levels.Studies have indicated that the interaction of the
CD40-Lþ T lymphocytes augments the antigen pre-
senting function of CD40þ professional antigen-
presenting cells (APCs), which in turn stimulates
interacting CD4þ and CD8þ T-cells.9e11 As expected,
CD40 expressed by carcinoma cells has been shown to
serve a similar costimulatory role; CD40þ tumor cells
promote dendritic cell survival and proliferation and
differentiation of CD40Lþ cytotoxic T lymphocytes
(CTLs).12,13 Our data showed that sCD40 levels and
CD40Lþ T-cell ratios in pleural fluid were negatively
correlated to ADA and that ADA is one of the indicators
of T cell activation. We suggest that sCD40 secreted by
tumor cells could compete for binding and blocking of
CD40Lþ on T-cells and modulate the anti-tumor im-
mune function, resulting in increased tumor cell ability
to escape anti-tumor immune function. We have also
observed that there is no significant difference between
sCD40 levels and ADA in plasma, indicating that ma-
lignant pleural effusion, as a relatively typical tumor
micro-environment, has more value than plasma in
reflecting the immune status of lung cancer patients.
Many tumor cells express CD40, including nearly
100% of B-cell malignancies and up to 70% of solid
40 C.-Y. Mu et al. / Chronic Diseases and Translational Medicine 1 (2015) 36e41tumors, and CD40 expression has diverse
functions.14e19 In primary cutaneous melanoma, CD40
expression has been reported to be a negative prog-
nostic factor, and the expression of CD40 in metastatic
melanoma in situ is far weaker than in primary mela-
noma.20,21 Our study found that the median survival
time of patients with high levels of sCD40, more than
200 pg/ml, was significantly less than for those who
had lower levels, indicating sCD40 could be a prog-
nostic indicator for patients with lung cancer. Other
studies have found that engagement of CD40 in vitro
can inhibit the growth of solid tumor cells, and the
combination of an anti-CD40 agonist antibody and
gemcitabine cured most mice with established
implanted tumors, and the cured mice were resistant to
tumor rechallenge. This effect is absolutely dependent
on CD8þ T-cells and independent of CD4þ T-
cells.22e24 These analyses indicate that immune acti-
vation and direct tumor cytotoxicity after systemic
CD40 activation can have synergistic antitumor effects.
In summary, on lung carcinoma cells, CD40 is
presented in a non-immunogenic context and may
contribute to T-cell unresponsiveness, providing a thus
far unrecognized mechanism to evade anti-tumor im-
mune activity. The reversal of this CD40 dependent
inactivation may be important for future immunother-
apeutic approaches.
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